Amgen sees no bone safety concerns around experimental obesity drug

Forex Piața materiilor prime Piața bursieră Criptomonedă

(Reuters) - Amgen (NASDAQ:AMGN ) said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower.

Source: Investing.com

Publicații recente

Siemens shares higher on better-than-expected earnings

14.11.2024 - 10:00

Top Russian official Shoigu visits Zhuhai air show on final trade day

14.11.2024 - 10:00

European stocks mixed; ASML shines ahead of eurozone growth data

14.11.2024 - 10:00

Aviva posts strong Q3 trading update, shares up

14.11.2024 - 10:00

Crypto market cap hits record $3.2 trillion, CoinGecko data shows

14.11.2024 - 10:00

Energy, tech stocks boost European shares at open

14.11.2024 - 10:00

Indonesia stocks lower at close of trade; IDX Composite Index down 0.88%

14.11.2024 - 10:00

Japan's SMFG lifts profit forecasts after Q2 net income rises 27%

14.11.2024 - 10:00

Telecoms group VEON mulls U.S. IPO for Ukraine's Kyivstar

14.11.2024 - 10:00

Foxconn sees robust AI server demand, posts 14% rise in Q3 profit

14.11.2024 - 09:00

Japan stocks lower at close of trade; Nikkei 225 down 0.61%

14.11.2024 - 09:00

ASML sees growth continuing through 2030 on AI demand

14.11.2024 - 09:00

Mizuho lifts annual guidance after bumper Q2 as rate hikes boost margins

14.11.2024 - 09:00

Australia's Woolworths, Coles face class action over dodgy discount claims

14.11.2024 - 09:00

Japan's MUFG lifts profit forecasts after Q2 net income nearly doubles

14.11.2024 - 09:00

Analiza pieței Cum va afecta raportul NFP de mâine cursul de schimb al dolarului american?